Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Use of Salvage Plus ASCT in DLBCL With End-Stage Renal Disease

Key clinical point: A case of refractory diffuse large B-cell lymphoma (DLBCL) with comorbid end-stage renal disease was successfully treated with modified salvage chemotherapy and autologous stem cell transplantation (ASCT).

Major finding: After receiving dose-adjusted rituximab, gemcitabine, dexamethasone, and carboplatin (R-GDC), followed by modified salvage chemotherapy and ASCT, the patient achieved complete remission.

Study details: A clinical case report of one 55-year-old man with refractory DLBCL and dialysis-dependent end-stage renal disease.

Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.

Citation:

Morita K et al. Clin Lymphoma Myeloma Leuk. 2019 Nov 7. doi: 10.1016/j.clml.2019.11.004.